Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Thomas Mika, Katharina Strate, Swetlana Ladigan, Clemens Aigner, Uwe Schlegel, Iris Tischoff, Sabine Tischer-Zimmermann, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Roland Schroers
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2019-12-01
Edice:	Frontiers in Medicine
Témata:	PTLD alloHSCT aggressive lymphoma brentuximab vedotin (BV) third-party EBV-specific T-lymphocytes
On-line přístup:	https://www.frontiersin.org/article/10.3389/fmed.2019.00295/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!